There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Gossamer Bio Inc (GOSS) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.0134, or -2.30%, to $0.5701. The Gossamer Bio Inc has recorded 8,944 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs.
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $0.58 and fluctuated between $0.6000 as its day high and $0.5600 as its day low. The current market capitalization of Gossamer Bio Inc is $131.47M. A total of 1.18 million shares were traded on the day, compared to an average of 1.99M shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, GOSS has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 9 BUYs and 4 SELLs from insiders. Insiders purchased 1,609,772 shares during that period but sold 22,970.
In the most recent transaction, Aranda Richard sold 1,814 shares of GOSS for 1.29 per share on Jun 22. After the transaction, the Chief Medical Officer now owns 197,574 company shares. In a previous transaction on Apr 04, Giraudo Bryan bought 55,000 shares at 1.02 per share. GOSS shares that COO/CFO owns now total 125,990.
Among the insiders who bought shares, Hasnain Faheem acquired of 440,500 shares on Mar 22 at a per-share price of $1.14. This resulted in the President & CEO holding 4,495,897 shares of GOSS after the transaction. In another insider transaction, Hasnain Faheem bought 269,389 shares at $1.20 per share on Mar 21. Company shares held by the President & CEO now total 4,055,397.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for GOSS in the last 3 months, the mean price target is $5.31 with high estimates of $15.00 and low estimates of $1.25. In terms of 52-week highs and lows, GOSS has a high of $10.57 and a low of $0.45.
As of this writing, GOSS has an earnings estimate of -$0.26 per share for the current quarter. EPS was calculated based on a consensus of 10 estimates, with a high estimate of -$0.18 per share and a lower estimate of -$0.65. The company reported an EPS of -$0.52 in the last quarter, which was 1.90% higher than expectations of -$0.53.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. GOSS’s latest balance sheet shows that the firm has $325.22M in Cash & Short Term Investments as of fiscal 2021. There were $185.24M in debt and $39.86M in liabilities at the time. Its Book Value Per Share was -$0.66, while its Total Shareholder’s Equity was $121.46M.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for GOSS is Buy with a score of 4.00.